Clients’ experiences on North America’s first take-home injectable opioid agonist treatment (iOAT) program: a qualitative study

[1]  Scott Harrison,et al.  Provider experiences with relaxing restrictions on take-home medications for opioid use disorder during the COVID-19 pandemic: A qualitative systematic review , 2023, The International journal on drug policy.

[2]  G. Dore,et al.  “You'll come in and dose even in a global pandemic”: A qualitative study of adaptive opioid agonist treatment provision during the COVID-19 pandemic , 2023, International Journal of Drug Policy.

[3]  N. Bansback,et al.  Feasibility of Testing Client Preferences for Accessing Injectable Opioid Agonist Treatment (iOAT): A Pilot Study , 2022, Patient preference and adherence.

[4]  H. Eyford,et al.  Prescribing safe supply: ethical considerations for clinicians , 2022, Journal of Medical Ethics.

[5]  F. Kouyoumdjian,et al.  Opioid agonist treatment take-home doses (‘carries’): Are current guidelines resulting in low treatment coverage among high-risk populations in Canada and the USA? , 2022, Harm Reduction Journal.

[6]  Kim A. Hoffman,et al.  Treatment retention, return to use, and recovery support following COVID-19 relaxation of methadone take-home dosing in two rural opioid treatment programs: A mixed methods analysis , 2022, Journal of Substance Abuse Treatment.

[7]  T. Gomes,et al.  Association Between Increased Dispensing of Opioid Agonist Therapy Take-Home Doses and Opioid Overdose and Treatment Interruption and Discontinuation. , 2022, JAMA.

[8]  T. Gomes,et al.  Impact of the COVID-19 pandemic on the provision of take-home doses of opioid agonist therapy in Ontario, Canada: A population-based time-series analysis , 2022, International Journal of Drug Policy.

[9]  B. Hutton,et al.  Evaluating how has care been affected by the Ontario COVID-19 Opioid Agonist Treatment Guidance: Patients’ and prescribers’ experiences with changes in unsupervised dosing , 2021, International Journal of Drug Policy.

[10]  M. Vogel,et al.  Experiences with take-home dosing in heroin-assisted treatment in Switzerland during the COVID-19 pandemic–Is an update of legal restrictions warranted? , 2021, International Journal of Drug Policy.

[11]  O. Amram,et al.  The impact of relaxation of methadone take-home protocols on treatment outcomes in the COVID-19 era , 2021, The American journal of drug and alcohol abuse.

[12]  Sandra H. Sulzer,et al.  Treatment provider perceptions of take-home methadone regulation before and during COVID-19 , 2021, Drug and Alcohol Dependence.

[13]  N. Lintzeris,et al.  Opioid agonist treatment and patient outcomes during the COVID‐19 pandemic in south east Sydney, Australia , 2021, Drug and alcohol review.

[14]  W. van den Brink,et al.  The suitability of oral diacetylmorphine in treatment-refractory patients with heroin dependence: A scoping review. , 2021, Drug and alcohol dependence.

[15]  K. Knight,et al.  “The Idea is to Help People Achieve Greater Success and Liberty”: A Qualitative Study of Expanded Methadone Take-Home Access in Opioid Use Disorder Treatment , 2021, medRxiv.

[16]  P. Mateu-Gelabert,et al.  “It’s like ‘liquid handcuffs”: The effects of take-home dosing policies on Methadone Maintenance Treatment (MMT) patients’ lives , 2021, Harm Reduction Journal.

[17]  L. Degenhardt,et al.  Association of Opioid Agonist Treatment With All-Cause Mortality and Specific Causes of Death Among People With Opioid Dependence: A Systematic Review and Meta-analysis. , 2021, JAMA psychiatry.

[18]  M. Schechter,et al.  A multi-methods and longitudinal study of patients' perceptions in injectable opioid agonist treatment: Implications for advancing patient-centered methodologies in substance use research. , 2021, Journal of substance abuse treatment.

[19]  T. Kerr,et al.  "People need them or else they're going to take fentanyl and die": A qualitative study examining the 'problem' of prescription opioid diversion during an overdose epidemic. , 2021, Social science & medicine.

[20]  T. Kerr,et al.  Examining factors that shape use and access to diverted prescription opioids during an overdose crisis: A qualitative study in Vancouver, Canada. , 2021, Journal of substance abuse treatment.

[21]  P. Carrieri,et al.  Individual and structural correlates of willingness for intravenous buprenorphine treatment among people who inject sublingual buprenorphine in France , 2021, Harm Reduction Journal.

[22]  E. Oviedo-Joekes,et al.  Take home injectable opioids for opioid use disorder during and after the COVID-19 Pandemic is in urgent need: a case study , 2020, Substance Abuse Treatment, Prevention, and Policy.

[23]  F. Altice,et al.  Rapid transitional response to the COVID-19 pandemic by opioid agonist treatment programs in Ukraine , 2020, Journal of Substance Abuse Treatment.

[24]  N. Dasgupta,et al.  Take-home dosing experiences among persons receiving methadone maintenance treatment during COVID-19 , 2020, Journal of Substance Abuse Treatment.

[25]  Fay Dennis.  Advocating for diamorphine: Cosmopolitical care and collective action in the ruins of the ‘old British system’ , 2020, Critical public health.

[26]  Ketra L. Rice,et al.  The economic burden of opioid use disorder and fatal opioid overdose in the United States, 2017. , 2020, Drug and alcohol dependence.

[27]  L. Bromley.  Problems with hydromorphone prescribing as a response to the opioid crisis , 2020, Canadian Medical Association Journal.

[28]  E. Stuart,et al.  Opioid agonist treatment and fatal overdose risk in a state-wide US population receiving opioid use disorder services. , 2020, Addiction.

[29]  M. Schechter,et al.  Building healthcare provider relationships for patient-centered care: A qualitative study of the experiences of people receiving injectable opioid agonist treatment , 2020, Substance abuse treatment, prevention, and policy.

[30]  Dennis Reidsma,et al.  Review Committee , 1983, 2020 International Conference on Futuristic Technologies in Control Systems & Renewable Energy (ICFCR).

[31]  S. Nixon,et al.  Two approaches to longitudinal qualitative analyses in rehabilitation and disability research , 2020, Disability and rehabilitation.

[32]  P. Friedmann,et al.  Correlates of Patient-Centered Care Practices at U.S. Substance Use Disorder Clinics. , 2020, Psychiatric services.

[33]  D. McCarty,et al.  Comparing Canadian and United States opioid agonist therapy policies. , 2019, The International journal on drug policy.

[34]  B. Le Foll,et al.  Injectable opioid agonist treatment for opioid use disorder: a national clinical guideline , 2019, Canadian Medical Association Journal.

[35]  M. Schechter,et al.  Conceptualizing patient-centered care for substance use disorder treatment: findings from a systematic scoping review , 2019, Substance Abuse Treatment, Prevention, and Policy.

[36]  Philip R. Kavanaugh,et al.  "They're making it so hard for people to get help:" Motivations for non-prescribed buprenorphine use in a time of treatment expansion. , 2019, The International journal on drug policy.

[37]  Virginia Braun,et al.  Reflecting on reflexive thematic analysis , 2019, Qualitative Research in Sport, Exercise and Health.

[38]  M. Schechter,et al.  Adverse Events During Treatment Induction With Injectable Diacetylmorphine and Hydromorphone for Opioid Use Disorder , 2019, Journal of addiction medicine.

[39]  Lucie M. Bucci.  Health Canada , 2019, The Grants Register 2022.

[40]  Jacek Kopec,et al.  The global burden of disease attributable to alcohol and drug use in 195 countries and territories, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016 , 2018, The lancet. Psychiatry.

[41]  P. George,et al.  Opioid Overdose Hospitalizations among Medicare-Disability Beneficiaries , 2018, The Journal of the American Board of Family Medicine.

[42]  O. Amram,et al.  Increased distance was associated with lower daily attendance to an opioid treatment program in Spokane County Washington. , 2018, Journal of substance abuse treatment.

[43]  R. Frank,et al.  Making the Opioid Public Health Emergency Effective , 2018, JAMA psychiatry.

[44]  N. Bansback,et al.  Cost‐effectiveness of hydromorphone for severe opioid use disorder: findings from the SALOME randomized clinical trial , 2018, Addiction.

[45]  Huiru Dong,et al.  Increasing diversion of methadone in Vancouver, Canada, 2005-2015. , 2018, Journal of substance abuse treatment.

[46]  L. Strang,et al.  Heroin-Assisted Treatment and Supervised Drug Consumption Sites: Experience from Four Countries , 2018 .

[47]  B. Spire,et al.  Willingness to receive intravenous buprenorphine treatment in opioid-dependent people refractory to oral opioid maintenance treatment: results from a community-based survey in France , 2017, Substance Abuse Treatment, Prevention, and Policy.

[48]  M. Schechter,et al.  Safety profile of injectable hydromorphone and diacetylmorphine for long-term severe opioid use disorder. , 2017, Drug and alcohol dependence.

[49]  M. Schechter,et al.  Men’s and women’s response to treatment and perceptions of outcomes in a randomized controlled trial of injectable opioid assisted treatment for severe opioid use disorder , 2017, Substance Abuse Treatment, Prevention, and Policy.

[50]  P. Krajči,et al.  Addressing misuse and diversion of opioid substitution medication: guidance based on systematic evidence review and real-world experience. , 2016, Journal of public health.

[51]  M. Schechter,et al.  Hydromorphone Compared With Diacetylmorphine for Long-term Opioid Dependence: A Randomized Clinical Trial. , 2016, JAMA psychiatry.

[52]  Lampros Samartzis,et al.  Opioid substitution therapy: Lowering the treatment thresholds. , 2016, Drug and alcohol dependence.

[53]  C. Browne.  Critical Social Theory , 2016 .

[54]  P. Krajči,et al.  The Impact of Misuse and Diversion of Opioid Substitution Treatment Medicines: Evidence Review and Expert Consensus , 2015, European Addiction Research.

[55]  J. Bell,et al.  Heroin on trial: Systematic review and meta-analysis of randomised trials of diamorphine-prescribing as treatment for refractory heroin addiction , 2015, British Journal of Psychiatry.

[56]  Jörg Dirmaier,et al.  An Integrative Model of Patient-Centeredness – A Systematic Review and Concept Analysis , 2014, PloS one.

[57]  C. Ruckes,et al.  Maintenance treatment for opioid dependence with slow-release oral morphine: a randomized cross-over, non-inferiority study versus methadone , 2014, Addiction.

[58]  R. Kling,et al.  Recent trends in substance abuse among persons with disabilities compared to that of persons without disabilities. , 2013, Disability and health journal.

[59]  L. Arendt-Nielsen,et al.  Differences between opioids: pharmacological, experimental, clinical and economical perspectives , 2013, British journal of clinical pharmacology.

[60]  N. Bansback,et al.  Cost-effectiveness of diacetylmorphine versus methadone for chronic opioid dependence refractory to treatment , 2012, Canadian Medical Association Journal.

[61]  J. Strang,et al.  New heroin-assisted treatment: Recent evidence and current practices of supervised injectable heroin treatment in Europe and beyond , 2012 .

[62]  Karen K. Yoshida,et al.  Qualitative Research in Sport, Exercise and Health , 2012 .

[63]  M. Ferri,et al.  Heroin maintenance for chronic heroin-dependent individuals. , 2011, The Cochrane database of systematic reviews.

[64]  A. Winstock,et al.  Definitions related to the use of pharmaceutical opioids: extramedical use, diversion, non-adherence and aberrant medication-related behaviours. , 2011, Drug and alcohol review.

[65]  T. Ajayi.  Drug Misuse and Dependence: UK Guidelines on Clinical Management , 2008 .

[66]  S. Thorne,et al.  The Analytic Challenge in Interpretive Description , 2004 .

[67]  R P Mattick,et al.  Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. , 2008, The Cochrane database of systematic reviews.

[68]  J. Jaffe,et al.  From morphine clinics to buprenorphine: regulating opioid agonist treatment of addiction in the United States. , 2003, Drug and alcohol dependence.

[69]  R P Mattick,et al.  Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. , 2009, The Cochrane database of systematic reviews.

[70]  P. Bower,et al.  Patient-centredness: a conceptual framework and review of the empirical literature. , 2000, Social science & medicine.

[71]  J. Fountain,et al.  Diversion of prescribed drugs by drug users in treatment: analysis of the UK market and new data from London. , 2000, Addiction.

[72]  J. Strang,et al.  Heroin Prescribing in the British System: Historical Review , 1996 .

[73]  A. Strauss,et al.  Grounded theory , 2017 .

[74]  R. D'amico.  Discipline and Punish: The Birth of the Prison , 1978, Telos.